

ISCD Relationships with Industry

The mission of The International Society for Clinical Densitometry (ISCD) is to advance excellence in the assessment of skeletal health by:

- Promoting education and a broader understanding of the clinical applications of bone mass measurement and other skeletal health assessment technologies
- Assuring proficiency in the assessment of skeletal health through certification and accreditation
- Supporting clinical and scientific advances in the field
- Ensuring patient access to bone mass measurement and other skeletal health assessment technologies by supporting the debate on cost and accessibility of densitometry.

The ISCD recognizes the important benefits of partnering with industry (for-profit organizations that may have a conflict of interest with the mission of The ISCD) that have led to major medical advances, thereby improving human health. The common interests of healthcare providers and industry to advance medical care makes collaboration valuable. Even so, there are potential risks with any relationship that includes the financial goals of industry, and these may at times conflict with the professional goals of The ISCD (1, 2). It is a principle of the ISCD that collaborating with and accepting financial support from industry does not necessarily reflect a conflict of interest. The ISCD has had in place for some time protective measures as noted below:

1) Educational Programs of the ISCD (CME events)

All CME events will follow ACCME Standards for Commercial Support and other appropriate local regulatory guidelines (3, 4).

2) Position Development Conferences (PDC)

a) Support

In keeping with established guidelines for accepting commercial support from industry, support from industry for the PDC, if offered and considered appropriate, will be accepted in the form of educational grants for both the program and subsequent publications.

b) Participation of Industry in the PDC

Employees of industry who have expertise, not otherwise available, may provide knowledge crucial to the PDC topics. Employees of industry may suggest, but cannot determine the PDC topics, content, or the Official Positions generated from the PDC.

3) Non CME Programs

a) Influence on Content

All non-CME programs of The ISCD are independent of all industry influence and as such industry will have no influence on the content.

b) Commercial Support

In keeping with established guidelines for accepting commercial support from industry, support for any non-CME program will be accepted in the form of educational grants for both the program and subsequent publications.

c) Transparency and disclosure

There will be full transparency and disclosure of financial relationships.

4) Disclosure of Board members and ISCD Committee Members Related to Relationships with Industry.

All members of The ISCD committees and Board members will provide disclosure of any financial relationships to industry.

5) General budgetary support

Financial support from industry will be accepted for the purpose of supporting the mission of The ISCD.

6) ISCD Publications

The content of The ISCD publications is free of industry influence. The Journal of Clinical Densitometry does accept paid advertising from industry.

7) Product endorsements

The ISCD will not endorse any industry products or services for the assessment or treatment of skeletal health.

REFERENCES

1. Institute of Medicine. Conflict of Interest in Medical Research, Education, and Practice. www.iom.edu/conflictinterest.
2. Steinbrook R. Controlling Conflicts of Interest- Proposals from the Institute of Medicine; NEJM 2009; 360; 2160-3.
3. Accreditation Council for Continuing Medical Education. ACCME Standards for Commercial Support. Standards to Ensure the Independence of CME Activities, <http://www.accme.org/>.
4. Accreditation Council on Continuing Medical Education. Annual Report, 2002, 7.

CONFLICT OF INTEREST INFORMATION FOR THE TASKFORCE PANEL

Sanford Baim, MD, CCD

Research: Lilly, Novartis, P&G, Merck, Roche, Amgen

Neil Binkley, MD, CCD

**Consultant: Merck, Novartis, Lilly
Speakers' Bureaus: Novartis, Merck, Roche, P&G, GSK**

Research: Merck, Novartis, Roche, Aventis, GSK, Deltanoid, Unigene

Consultant: Gilead Sciences

No Financial Relationships to Disclose

No Financial Relationships to Disclose

Catherine Gordon, MD

Larry G. Jankowski, CDT

Edward S. Leib, MD, CCD

Michael Lewiecki, MD, CCD

Research: Amgen, Eli Lilly, GSK, Novartis, Pfizer, P&G, Roche, Sanofi-Aventis, Wyeth

Consulting: Amgen, Eli Lilly, Novartis, Roche/GSK, Upsher-Smith, Wyeth

Speakers' Bureaus: Eli Lilly, Novartis, Roche/GSK

Ownership Interest: General Electric, P&G, Teva

Sarah Morgan, MD, CCD

Consulting: Amgen, Roche, Eli Lilly, P&G

Honoraria for speaking: Novartis, Roche/GSK, Sciele, Eli Lilly, P&G

Research: Roche

Christopher R. Shuhart, MD, CCD

Stockholder: Cubist Pharmaceuticals

Grant Recipient: Hoffman-LaRoche, Inc.

S. Bobo Tanner, MD, CCD

Consulting: Genentech, P&G, Biogen Idec

Speakers' Bureaus: Merck, P&G, Sanofi-Aventis, Wyeth, Amgen, Novartis, Roche/GSK, Lilly

Research: Roche, Genentech, Lilly, Wyeth, CSL, Greer

Rogene Tesar, PhD, CDBT, CCD

No Financial Relationships to Disclose

Nelson Watts, MD, CCD

Consulting: Amgen, Lilly, Novartis, Novo Nordisk, P&G, Sanofi-Aventis

Honoraria for speaking: Amgen, Novartis, P&G, Sanofi-Aventis

Research: Amgen, Lilly, Merck, Novartis, P&G, Sanofi-Aventis